Press release

CUTISS AG Raises CHF 7.255.000 in a Series A Financing to Advance Personalized Skin Graft Technologies

Funding brings resources to scale-up the production of denovoSkin™ and to develop the next generation skin grafts.

Zurich, Switzerland, June 20th 2018 – CUTISS AG, a biotech company spin-off of the University of Zurich (UZH), focused on the development of personalized bioengineered skin graft products for the treatment of skin defects, announces the closing of a series A financing round of CHF 7.255.000. CUTISS AG’s lead product denovoSkin™ has successfully completed Phase I in pediatric patients and is recruiting in multi-centric Phase II studies financed by Wyss Zurich. This series A financing round is succeeding a CHF 1 million convertible loan previously provided to the company by the UZH Life Sciences Fund, and now converted.

The funds raised with Giammaria Giuliani (Lead), Yellowstone Holding AG, Zürcher Kantonalbank and several private investors will be used to scale up the production of denovoSkin™ and to develop the next generation skin grafts. “Our Series A investors bring not only capital resources, but also great vision and experience in the Life Science industry and innovation. We are very glad to welcome them on board,” said Dr. Daniela Marino, CEO and co-founder of CUTISS AG.

The Lead investor, Giammaria Giuliani said: “We are thrilled to invest in a strong team that, we believe, will develop CUTISS AG’s technology into being a game changer in the cell therapy field for recon-structive and plastic surgery”. Branford Lu from Yellowstone Holding said: “It is our pleasure to work with CUTISS AG. We are confident that this technology will be of great benefit for millions of patients worldwide”.

CUTISS AG’s board of Directors is chaired by Prof. Dr. med. Martin Meuli, Director of the Surgery Department of the University Chil-dren’s Hospital Zurich. In conjunction with the financing, Giammaria Giuliani is joining the board with its other members: Prof. Dr. Ernst Reichmann, Head of the Tissue Biology Research Unit at the Univer-sity Children’s Hospital in Zurich, Dr. Anja König, Global Head of No-vartis Venture Fund and Dr. Daniela Marino.

About Skin Defects

Every year in the world, more than 50 millions of people suffer from skin defects and need surgical intervention to restore skin function. Skin defects can be either acute (burns & trauma) or elective (reconstructive and ulcers). In EU and US about 12 million patients could benefit from CUTISS AG’s technology every year. Burns are a rare disease and denovoSkin™ has received Orphan Drug Status / Designation for their treatment by Swissmedic, EMA and FDA. In many cases, standard of care leaves patients with debilitating scars. denovoSkin™ could significantly improve the life quality of patients worldwide by drastically reducing scarring after transplantation.

About CUTISS AG
CUTISS AG is a Swiss biotech company, spin-off of the UZH, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its first in line product denovoSkin™ has been tested in a phase I clinical trial on pediatric patients at the Uni-versity Children’s Hospital in Zurich. EU phase II studies have started financed by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ promises to improve life quality of elective (reconstructive) patients.

Contact
CUTISS AG, Daniela Marino, +41 76 230 8046, info@cutiss.swiss, www.cutiss.swiss

CUTISS AG receives Swissmedic approval to commence Phase IIb denovoSkin™ Trials in burns in adults and children.

Zurich, November 02, 2017 – CUTISS AG today announced that it has received approval from
Swissmedic to commence two Phase IIb Trials using denovoSkin™ in the treatment of burns in adults
and children. In Switzerland, these Trials will be recruiting patients at two centers, the University
Children’s Hospital Zurich where Phase I was recently completed, and the University Hospital Zurich.
The Trials will expand to other two centers, The Dutch Burn Center in The Netherlands, and the
University Hospital in Birmingham in UK, subject to approval by the National Authorities. The Trials
are designed to treat up to 15 burn patients each.

“The aim of these Phase IIb Trials is to validate the efficacy of denovoSkin™ against standard of care in
burns” said Dr. Fabienne Hartmann, CTO at CUTISS AG. “We are also delighted to continue the Trials
where they originated, at University Children’s Hospital Zurich. We want to thank the patients and
their families who have taken part in the trials so far and those that will support our future efforts”,
said Dr. Daniela Marino, CEO at CUTISS AG.

About Burns

Every year in the world, more than 11 millions of people burn large areas of their bodies and need
surgical intervention to restore skin function. In many cases, standard of care leaves patients with
discomforting and debilitating scars. denovoSkin™ could significantly improve the life quality of
patients worldwide by reducing scarring after transplantation.

About CUTISS AG
CUTISS AG is a Swiss biotech company, spin-off of the UZH, developing personalized skin graft
technologies for the treatment of a large spectrum of skin defects. Its first in line product denovoSkin™
has been tested in a Phase I Clinical Trial on pediatric patients at the University Children’s Hospital in
Zurich. EU Phase IIb Trials are funded by Wyss Zurich. denovoSkin™ has received Orphan Drug
Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™
promises to improve life quality of elective (reconstructive) patients, it is a scalable technology and it
can further be developed in terms of complexity by e.g. adding pigmentation.

Contact
CUTISS AG, Daniela Marino, +41 76 230 8046, info@cutiss.swiss, www.cutiss.swiss

Funding brings resources to start scale-up production of denovoSkin™.

Zurich, Switzerland, September 1st 2017 – CUTISS AG, a biotech company spin-off of the University
of Zurich (UZH), focused on the development of personalized bioengineered skin graft products for the
treatment of skin defects, announces the closing of a seed financing round of CHF 1 million. CUTISS’
lead product denovoSkin™ has successfully completed Phase I in pediatric patients and will initiate Phase
II studies in Q3/2017. The funds raised with UZH Life Sciences Fund investor will be used to launch the
development of the automation of the production process for denovoSkin™.

“The timing of this financing is perfect and puts CUTISS in a competitive position to efficiently continue
development of its proprietary technologies and personalized medicine products.” said Dr. Daniela
Marino, CEO and co-founder of CUTISS. “Launching of the scale-up activities represents a major
milestone of our process development.” added Dr. Vincent Ronfard, CIO of CUTISS. “The automation
project will bring GMP manufacturing to another level.” said Dr. Fabienne Hartmann, CTO and cofounder
of CUTISS. “We believe in CUTISS’ innovative product denovoskin™ for treating patients
suffering from skin defects,”, stated Anja König from the Novartis Venture Fund.
CUTISS’ board of Directors is chaired by Prof. Dr. med. Martin Meuli, a Key Opinion Leader in surgery
and skin tissue engineering. In conjunction with the financing, Anja König is joining the board with its
other founding members Prof. Dr. Ernst Reichmann, who leads the Tissue Biology Research Unit at the
University Children’s Hospital in Zurich where denovoSkin™ was developed, and Dr. Daniela Marino.